Julia G. Butchko Ph.D.
Net Worth

Last updated:

What is Julia G. Butchko Ph.D. net worth?

The estimated net worth of Dr. Julia G. Butchko Ph.D. is at least $11,912,395 as of 21 Aug 2024. He owns shares worth $6,535,012 as insider, has earned $2,722,383 from insider trading and has received compensation worth at least $2,655,000 in Immunovant, Inc..

What is the salary of Julia G. Butchko Ph.D.?

Dr. Julia G. Butchko Ph.D. salary is $531,000 per year as Chief Devel. & Technology Officer in Immunovant, Inc..

How old is Julia G. Butchko Ph.D.?

Dr. Julia G. Butchko Ph.D. is 54 years old, born in 1971.

What stocks does Julia G. Butchko Ph.D. currently own?

As insider, Dr. Julia G. Butchko Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Immunovant, Inc. (IMVT) Chief Devel. & Technology Officer 440,959 $14.82 $6,535,012

What does Immunovant, Inc. do?

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

IMVT logo
IMVT
Immunovant, Inc.
$14.82

Julia G. Butchko Ph.D. insider trading

Immunovant, Inc.

Dr. Julia G. Butchko Ph.D. has made 29 insider trades between 2020-2024, according to the Form 4 filled with the SEC. Most recently he sold 120 units of IMVT stock worth $3,878 on 21 Aug 2024.

The largest trade he's ever made was exercising 60,471 units of IMVT stock on 11 Jan 2023. As of 21 Aug 2024 he still owns at least 440,959 units of IMVT stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 120 $32.32 $3,878
Sale
Common Stock 2,907 $31.84 $92,559
Sale
Common Stock 2,698 $29.64 $79,969
Sale
Common Stock 169 $30.55 $5,163
Sale
Common Stock 1,527 $28.06 $42,848
Sale
Common Stock 3,247 $29.65 $96,274
Sale
Common Stock 2,290 $29.94 $68,563
Sale
Common Stock 7,825 $28.8 $225,360
Sale
Common Stock 1,053 $31.18 $32,833
Sale
Common Stock 2,146 $36.15 $77,578
Sale
Common Stock 1,297 $38.59 $50,051
Sale
Common Stock 3,141 $32.75 $102,868
Sale
Common Stock 124 $33.52 $4,156
Sale
Common Stock 1,439 $36.39 $52,365
Sale
Common Stock 296 $35.54 $10,520
Sale
Common Stock 12,332 $20.3 $250,340
Sale
Common Stock 1 $20.89 $21
Sale
Common Stock 1,470 $19.73 $29,003
Sale
Common Stock 1,544 $15.27 $23,577
Sale
Common Stock 19 $15.16 $288
Sale
Common Stock 60,471 $16.79 $1,015,308
Sale
Common Stock 928 $9.18 $8,519
Sale
Common Stock 548 $5.83 $3,195
Sale
Common Stock 510 $4.27 $2,178
Sale
Common Stock 460 $4.02 $1,849
Sale
Common Stock 492 $3.79 $1,865
Sale
Common Stock 541 $4.72 $2,554
Sale
Common Stock 6,381 $5.9 $37,648
Sale
Common Stock 55,318 $7.25 $401,056
Purchase
Common Stock 5,000 $38.17 $190,850

Immunovant key executives

Immunovant, Inc. executives and other stock owners filed with the SEC:

  • Dr. Frank M. Torti M.B.A., M.D., MBA (46) Executive Chairperson of the Board
  • Dr. Julia G. Butchko Ph.D. (54) Chief Devel. & Technology Officer
  • Dr. Peter Salzmann M.B.A., M.D. (57) Chief Executive Officer & Director